US Biotech Firm Apellis Is Said to Attract Takeover Interest
- Larger drugmakers are eyeing $7.6 billion company: sources
- Apellis shares rise as much as 12% in Monday premarket trading
Source: Tek Image/Science Photo Library/Getty Images
This article is for subscribers only.
Apellis Pharmaceuticals Inc., a biotech firm focused on rare diseases and ophthalmology, is drawing takeover interest from larger drugmakers, people with knowledge of the matter said.
The company is speaking to advisers to consider its options amid the interest, they said. Apellis may also consider seeking partnerships or licensing agreements for some of its ophthalmology products, the people said, asking not to be identified discussing confidential information.